Home › Funds › Pivotal bioVenture Partners Investment Advisor LLC › IMNM
Pivotal bioVenture Partners Investment Advisor LLC position in IMNM
IMMUNOME INC · Health Care
Pivotal bioVenture Partners Investment Advisor LLC reported holding 732,512 shares of IMNM (IMMUNOME INC) in its Q3 2026 13F filing — a position valued at US$15.8M, representing 6.42% of its reported portfolio and ranking #6 among its reported holdings. Pivotal bioVenture Partners Investment Advisor LLC has disclosed IMNM holdings in 5 of the last 5 reported quarters, going back to Q3 2025.
Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR
How Pivotal bioVenture Partners Investment Advisor LLC's IMNM position evolved
Pivotal bioVenture Partners Investment Advisor LLC first disclosed a stake in IMNM in Q3 2025 at 502,512 shares (US$5.9M). The position peaked in Q1 2026 at 732,512 shares, worth US$16.0M. Across 5 filings, Pivotal bioVenture Partners Investment Advisor LLC increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 3 time(s). The most recent filing (Q3 2026) shows 732,512 shares valued at US$15.8M. Notable position changes include a 46% increase in Q4 2025 (shares rose 2% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2025 | 502.51K | $5.88M | New |
| Q4 2025 | 732.51K | $15.73M | Add |
| Q1 2026 | 732.51K | $16.02M | Hold |
| Q2 2026 | 732.51K | $15.52M | Hold |
| Q3 2026 | 732.51K | $15.76M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About IMNM and 13F data
IMNM (IMMUNOME INC) is a Health Care company. 42 other funds we track also report a position in IMNM — the largest reported positions include Redmile Group, LLC (US$104.1M), Enavate Sciences GP, LLC (US$76.6M), SILVERARC CAPITAL MANAGEMENT, LLC (US$45.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding IMNM
- Redmile Group, LLC 4.91M sh · $104.08M · Q2 2026
- Enavate Sciences GP, LLC 3.61M sh · $76.58M · Q2 2026
- SILVERARC CAPITAL MANAGEMENT, LLC 2.09M sh · $45.01M · Q3 2026
- Sofinnova Investments, Inc. 1.72M sh · $36.45M · Q2 2026
- READYSTATE ASSET MANAGEMENT LP 1.61M sh · $34.03M · Q2 2026
- NAN FUNG TRINITY (HK) Ltd 621.08K sh · $13.36M · Q3 2026
- Parkman Healthcare Partners LLC 594.20K sh · $12.59M · Q2 2026
More on Pivotal bioVenture Partners Investment Advisor LLC
FAQ
How long has Pivotal bioVenture Partners Investment Advisor LLC held IMNM?
Pivotal bioVenture Partners Investment Advisor LLC has disclosed IMNM holdings in 5 of the last 5 reported quarters, going back to Q3 2025.
What is Pivotal bioVenture Partners Investment Advisor LLC's current position in IMNM?
As of Q3 2026, Pivotal bioVenture Partners Investment Advisor LLC holds 732.51K shares of IMNM (IMMUNOME INC), valued at $15.76M, representing 6.42% of its reported portfolio and ranking #6.
Has Pivotal bioVenture Partners Investment Advisor LLC been buying or selling IMNM?
In the latest 13F filing (Q3 2026), Pivotal bioVenture Partners Investment Advisor LLC held unchanged its position in IMNM. The position peaked in Q1 2026 at 732.51K shares.
Which other funds hold IMNM?
Other major institutional holders of IMNM include Redmile Group, LLC, Enavate Sciences GP, LLC, SILVERARC CAPITAL MANAGEMENT, LLC, among 42 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.